MacGrogan G - Search Results

1

Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.

Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD. Verbeke S, et al. Among authors: macgrogan g. Breast Cancer Res. 2014 Dec 20;16(6):504. doi: 10.1186/s13058-014-0504-9. Breast Cancer Res. 2014. PMID: 25527189 Free PMC article.

2

Erratum to: Humanization of the mouse mammary gland by replacement of the luminal layer with genetically engineered preneoplastic human cells.

Verbeke S, Richard E, Monceau E, Schmidt X, Rousseau B, Velasco V, Bernard D, Bonnefoi H, MacGrogan G, Iggo RD. Verbeke S, et al. Among authors: macgrogan g. Breast Cancer Res. 2015 Sep 16;17(1):126. doi: 10.1186/s13058-015-0612-1. Breast Cancer Res. 2015. PMID: 26376855 Free PMC article.

3

The mammary ducts create a favourable microenvironment for xenografting of luminal and molecular apocrine breast tumours.

Richard E, Grellety T, Velasco V, MacGrogan G, Bonnefoi H, Iggo R. Richard E, et al. Among authors: macgrogan g. J Pathol. 2016 Nov;240(3):256-261. doi: 10.1002/path.4772. Epub 2016 Sep 29. J Pathol. 2016. PMID: 27447842

4

Molecular apocrine differentiation is a common feature of breast cancer in patients with germline PTEN mutations.

Banneau G, Guedj M, MacGrogan G, de Mascarel I, Velasco V, Schiappa R, Bonadona V, David A, Dugast C, Gilbert-Dussardier B, Ingster O, Vabres P, Caux F, de Reynies A, Iggo R, Sevenet N, Bonnet F, Longy M. Banneau G, et al. Among authors: macgrogan g. Breast Cancer Res. 2010;12(4):R63. doi: 10.1186/bcr2626. Epub 2010 Aug 16. Breast Cancer Res. 2010. PMID: 20712882 Free PMC article.

5

Residual cancer burden index and tumor-infiltrating lymphocyte subtypes in triple-negative breast cancer after neoadjuvant chemotherapy.

Pinard C, Debled M, Ben Rejeb H, Velasco V, Tunon de Lara C, Hoppe S, Richard E, Brouste V, Bonnefoi H, MacGrogan G. Pinard C, et al. Among authors: macgrogan g. Breast Cancer Res Treat. 2020 Jan;179(1):11-23. doi: 10.1007/s10549-019-05437-z. Epub 2019 Sep 16. Breast Cancer Res Treat. 2020. PMID: 31529299

6

Expression of neurotensin receptor-1 (NTS₁) in primary breast tumors, cellular distribution, and association with clinical and biological factors.

Morgat C, Brouste V, Chastel A, Vélasco V, Macgrogan G, Hindié E. Morgat C, et al. Among authors: macgrogan g. Breast Cancer Res Treat. 2021 Dec;190(3):403-413. doi: 10.1007/s10549-021-06402-5. Epub 2021 Oct 1. Breast Cancer Res Treat. 2021. PMID: 34596798

7

Enhancing Abiraterone Acetate Efficacy in Androgen Receptor-positive Triple-negative Breast Cancer: Chk1 as a Potential Target.

Grellety T, Callens C, Richard E, Briaux A, Vélasco V, Pulido M, Gonçalves A, Gestraud P, MacGrogan G, Bonnefoi H, Cardinaud B. Grellety T, et al. Among authors: macgrogan g. Clin Cancer Res. 2019 Jan 15;25(2):856-867. doi: 10.1158/1078-0432.CCR-18-1469. Epub 2018 Oct 23. Clin Cancer Res. 2019. PMID: 30352905

8

Patterns of genomic change in residual disease after neoadjuvant chemotherapy for estrogen receptor-positive and HER2-negative breast cancer.

Chatzipli A, Bonnefoi H, MacGrogan G, Sentis J, Cameron D, Poncet C; EORTC 10994/BIG 1-00 Consortium; Iggo R. Chatzipli A, et al. Among authors: macgrogan g. Br J Cancer. 2021 Nov;125(10):1356-1364. doi: 10.1038/s41416-021-01526-3. Epub 2021 Sep 3. Br J Cancer. 2021. PMID: 34480095 Free PMC article. Clinical Trial.

9

Expression of Gastrin-Releasing Peptide Receptor in Breast Cancer and Its Association with Pathologic, Biologic, and Clinical Parameters: A Study of 1,432 Primary Tumors.

Morgat C, MacGrogan G, Brouste V, Vélasco V, Sévenet N, Bonnefoi H, Fernandez P, Debled M, Hindié E. Morgat C, et al. Among authors: macgrogan g. J Nucl Med. 2017 Sep;58(9):1401-1407. doi: 10.2967/jnumed.116.188011. Epub 2017 Mar 9. J Nucl Med. 2017. PMID: 28280221 Free article.

10

Clinical and genomic analysis of a randomised phase II study evaluating anastrozole and fulvestrant in postmenopausal patients treated for large operable or locally advanced hormone-receptor-positive breast cancer.

Quenel-Tueux N, Debled M, Rudewicz J, MacGrogan G, Pulido M, Mauriac L, Dalenc F, Bachelot T, Lortal B, Breton-Callu C, Madranges N, de Lara CT, Fournier M, Bonnefoi H, Soueidan H, Nikolski M, Gros A, Daly C, Wood H, Rabbitts P, Iggo R. Quenel-Tueux N, et al. Among authors: macgrogan g. Br J Cancer. 2015 Aug 11;113(4):585-94. doi: 10.1038/bjc.2015.247. Epub 2015 Jul 14. Br J Cancer. 2015. PMID: 26171933 Free PMC article. Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

222 results

Search Page